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Abstract
Purpose The use of antidepressants during pregnancy is
common. Some studies suggest an association between in
utero exposure to antidepressants and the occurrence of
pulmonary diseases like asthma later in life. Serotonin reup-
take inhibitors (SSRIs) as well tricyclic antidepressants
(TCAs) are thought to be involved in the development of
the respiratory rhythm generator (RRG) and the maturation
of the formation of surfactant. In this study the use of drugs
for pulmonary diseases in children who were exposed to
antidepressants in utero were compared with non-exposed
children.
Methods The pharmacy prescription database IADB.nl was
used for a cohort study in which the use of drugs for
pulmonary disease in children after in utero exposure to
antidepressants (TCAs, SSRIs) was compared with children
with no antidepressant exposure in utero. Drugs for pulmo-
nary diseases were applied as a proxy for disturbed develop-
ment of the respiratory tract.
Results A small though significant increase in the incidence
risk ratio (IRR) of the use of drugs for pulmonary disease
was found after any-time in utero exposure to SSRIs,
adjusted for maternal use of antibiotics, of 1.17 (95 % CI
1.16–1.18). An increase was also seen when we looked
specifically for the use of SSRIs in at least the first trimester
(IRR01.18, 95 % CI 1.17–1.20). An increased IRR in the
use of drugs for pulmonary disease was also seen when
children were exposed to TCAs, but this was not statistically
significant. However, in both groups our sample size was
rather small. The effect size is modest and may also be
confounded by maternal smoking.
Conclusions In utero exposure to SSRIs leads to a statisti-
cally significant increase in the use of drugs for pulmonary
diseases, especially when exposure occurred during the first
trimester of pregnancy. The increase in the use of drugs for
pulmonary disease may also be related to other factors.
Therefore, further study is recommended.
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Introduction
It has been estimated that up to 70 % of pregnant women
experience some symptoms of depression, with 10–16 % of
pregnant women fulfilling diagnostic criteria for a major
depressive disorder [1, 2]. Drugs of choice during pregnan-
cy for maternal depression are tricyclic antidepressants
(TCAs) and fluoxetine, a serotonin reuptake inhibitor
(SSRIs) [3]. Because of recent discussions about the efficacy
of SSRIs in general, the use of SSRIs during pregnancy should
be reconsidered [4]. However, the use of SSRIs has increased
two- to fourfold in western society during the last decade and
is therefore of importance for study [5, 6].
Most studies found no teratogenic effects for TCAs in
general [7], although one Swedish study identified an
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association between maternal clomipramine use and con-
genital cardiovascular anomalies such as ventricular or atrial
septal defects [8].
For SSRIs, studies have been published where paroxetine
and maybe bupropion, sertraline and citalopram are at risk
for cardiac congenital anomalies [9–15]. Paroxetine and also
venlafaxin and fluoxetine, are at risk of pulmonary hyper-
tension [16–19]. Further, SSRIs are possibly associated with
an increased risk of omphalocele, anencephaly, and cranio-
synostosis [20]. Of interest is the study of Reis et al. where
an increase in respiratory diagnosis (according to ICD-10
definitions) after in utero exposure to antidepressants was
found [21]. In relation with studies about pulmonary hyper-
tension associated with use of SSRIs it is worthwhile inves-
tigating further relations between in utero exposure of
antidepressants and fetal lung development.
The respiratory tract develops after 4 weeks of concep-
tion from the ventral wall of the foregut. The epithelium of
the internal lining of the respiratory system is of endodermal
origin. Muscular and connective tissues are derived from the
splanchic mesoderm. Up to the seventh prenatal month the
bronchioles divide continuously into more and smaller
canals (canalicular phase) and the vascular supply increases
steadily. Respiration becomes possible when some of the
cells of the cuboical respiratory bronchioles change into thin
flat cells. The cells are intimately associated with numerous
blood and lymph capillaries, and the surrounding spaces are
now primitive alveoli. At the end of the sixth month type 2
alveolar cells produce surfactant, a phospholipid rich fluid
capable of lowering surface tension at the air-alveolar
interface [22].
Serotonin (5-HT) from pulmonary neuro-endocrine cells
(PNECS) and serotonin cells in the raphe nucleus may have
different effects on the developing respiratory tract. 5-HT
modulates via the 5-HT1a receptor, the respiratory rhythm
generator (RRG) [23, 24]. Further, 5-HT modulates, proba-
bly via the 5-HT1B receptor and regulated by serotonin
transporters, pulmonary vasoconstriction in mice, rats, and
hamsters [25, 26], and depression of the phrenic motor
neurons [23]. The 5-HT2A-receptor is involved in the tonic
firing of phrenic motor neurons [23]. Activation of the 5-
HT2B-receptor leads to elevated respiratory activity via the
pre-Bötzinger complex (PBC) [27]. Together with the
5-HT2A-receptor, the 5-HT1B receptor is crucial for sus-
tained spontaneous respiratory activity [27]. 5-HT from
PNECS induces mechanical stretch of the lungs, which
stimulates proliferation and maturation of fetal lung cells
and the production of surfactant [28]. These findings together
make SSRIs that enhance 5-HT action in the synaptic cleft,
and may influence fetal lung function.
The other pharmacological class of antidepressants,
TCAs, may also have an influence on the fetal development
of the respiratory tract. TCA administration leads to elevated
levels of norepinephrine. Administration of isoxsuprine, a
β-adrenergic agonist, influences the production of surfactant
[29, 30]. This is in contrast to an α-adrenergic receptor
agonist (phenylephrine) [29]. Norepinephrine and other ago-
nists may also be involved via adrenergic receptors in the
activity of the RRG [31, 32]. These findings ensure that the
possible influence of TCAs on the fetal development of the
respiratory system cannot be ruled out.
The aim of this study was find out if in utero exposure of
antidepressants might lead to enhanced use of drugs for
pulmonary diseases. Therefore, we used as a proxy for
developmental respiratory tract changes compared with
non-exposure to antidepressants in particular, exposure of
antidepressants during the 2nd and 3rd trimesters. The time
periods are specific because of the involvement of antide-
pressants in the production of surfactant.
Materials and methods
This study was performed with the IADB.nl-database,
which contains pharmacy prescription data of an estimated
population of 500,000 individuals from the Netherlands.
Registration in the database is irrespective of health insur-
ance and is considered representative of the general popu-
lation. Each prescription record contains information on the
date of dispensing, the quantity dispensed, the dose regimen,
the number of days the prescription is valid, the prescribing
physician, and the Anatomical Therapeutic Chemical (ATC)
code. Each patient has a unique anonymous identifier; date of
birth and gender are known. Because of the high level of
patient–pharmacy commitment in the Netherlands, the
medication records for each patient are virtually complete,
except for OTC drugs and medication dispensed during
hospitalization.
The data for this study were obtained from the ‘Pregnancy
IADB’, which was extracted from the main IADB database.
Children were selected by date of birth and the female person
(15–50 years) with the same address code was considered to
be the mother [33]. Because only the child’s birth date is
known, the theoretical conception date was determined as
the date of birth minus 273 days (i.e., 9 months). The database
has been previously described [6, 34]. The data between 1995
and 2009 from the pregnancy database were used. Focusing
on our study objective, we determined the relative risk of the
use of drugs for pulmonary diseases in children after in utero
antidepressant exposure.
Study population, exposure and reference groups
We identified in the period 1995–2009, 35,546 children
from 23,576 women, as some women gave birth to more
than one child. The exposure to antidepressants was
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calculated during the three trimesters of pregnancy of each
woman. Exposure was defined as the theoretical period of
use: from dispensing date until the last day the prescription
was valid. Two exposure groups were formed, including
children of mothers exposed to TCAs (ATC code0
N06AA; n067) and children of mothers exposed to selec-
tive serotonin release inhibitors (SSRIs; ATC code0
N06AB; n0436) during pregnancy. We excluded children
who were exposed to any SSRI and any TCA (n010),
because of the interchangeable effects of both classes of
drugs. All prescriptions of TCAs with less than 0.5 DDDs
per day were excluded (n058), because TCAs are used for
treating neuropathic pain (which has not been associated
with pulmonary diseases) at a lower dose than for treating
depression, the disease that has been associated with asth-
ma. The time of exposure to antidepressants was divided
into the following periods: any time during pregnancy, only
the first trimester, only the second and third trimesters
combined, at least the first trimester, and at least the second
and third trimesters combined. The reference group con-
sisted of women who did not use any SSRIs or TCAs during
pregnancy and during a period of 7 days before pregnancy
(n035,033).
Drugs for pulmonary diseases
Drugs for pulmonary diseases in children were used as a
proxy for developmental respiratory tract changes in chil-
dren as a result of antidepressant exposure in utero. The use
of beta-2 selective sympathomimetics (ATC0R03CC, and
R03AC), inhalation corticosteroids (ATC0R03BA), com-
bined inhalation drugs (ATC0R03AK), and leucotriene
antagonists (ATC0R03DC) in children were studied in the
exposed groups and the reference group, and was regarded
as a proxy for developmental respiratory tract changes in
children if two or more prescriptions within 1 year were
found in our database.
Covariate analysis
From the literature we know that in utero exposure to anti-
biotics or benzodiazepines may lead to pulmonary diseases,
and also maternal diabetes, maternal age of delivery and
maternal (genetic) asthma, and may lead to pulmonary dis-
eases in the offspring. The exposure to these factors at any
time during pregnancy was considered a possible confound-
ing factor (see Discussion section). Therefore, we tested
with Chi-squared analysis for differences between the ex-
posed groups (Table 1). Those factors that differed between
the groups and significantly increased the IRR for use of
drugs for pulmonary disease, will be included in our calcu-
lations for adjusting the crude IRR.We calculated the adjusted
IRR with the formulas given in Rothman [35].
Analysis
The calculated day of conception was chosen as the starting
point to identify in which periods the children were exposed.
The day of birth of the children was chosen as a starting
point for the follow-up. The incidence rate (IR) of drugs for
pulmonary diseases used in the defined exposure groups
was calculated as the number of incident cases (drugs for
users with pulmonary diseases) divided by the time at risk
(in years). The time at risk was measured from the day of
birth until either the first prescription date, or the last known
date of the child in the database, or the end of the study
period, whichever occurred first. The exposure groups and
reference group were compared and the incidence risk ratio
(IRR) and 95 % confidence interval (CI) were calculated
according to Rothman [35].
Results
From the 35,400 pregnancies in our population, 36,323
children were born. Exposure to an SSRI anytime in preg-
nancy occurred in 436 children. Paroxetine was the most
commonly prescribed SSRI (n0266), followed by fluoxe-
tine (n0111), citalopram (n091), fluvoxamine (n070), ser-
traline (n034), and escitalopram (n011) (the sum of users
exceeds the number of SSRI users because of concomitant
use of two or more SSRIs or change of SSRI during preg-
nancy). Exposure to a TCA anytime in pregnancy occurred
in 67 children. The most commonly used TCAwas clomipr-
amine (n043), followed by amitriptyline (n031). In the
period 1995–2009, a total of 35,033 children were not
exposed to antidepressant medication.
We found a significant increase in the use of drugs for
pulmonary disease in children who were exposed to SSRIs
any time in utero (incidence risk ratio01.17; 95 % confi-
dence interval 1.16–1.18; Table 2). We also found an in-
creased risk when exposure was at least in the first trimester
(IRR01.18, 95 % CI 1.17–1.20). The increase, although not
statistically significant, was also found for TCAs where IRR
was 1.07 (95 % confidence interval 0.96–1.19; Table 2). The
size of the crude IRR of the use of drugs for pulmonary
disease due to antidepressant exposure was for all periods
during pregnancy more or less the same. However, adjusted
for concomitant antibiotic exposure, only the use of SSRIs,
at any time during the pregnancy and at least during the first
trimester, leads to a statistically significant increase in the
use of drugs for pulmonary disease.
Some possible confounding factors, like in utero expo-
sure to antibiotics and in utero exposure to insulin, showed a
significant increase in the use of drugs for pulmonary dis-
ease (Table 3). Therefore, differences between the groups
exposed to antidepressants combined with the increase due
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to confounding factors, leads to adjustment of the crude IRR
for maternal use of antibiotics. After adjustment, the effect
of the SSRIs on children exposed to antidepressants any
time during pregnancy and at least during the first trimester
turned into a significant increase in the use of drugs for
pulmonary disease (IRR01.17, 95 % CI 1.16–1.18; 95 % CI
1.17–1.20). Patient numbers of other time-frames of the
pregnancy were in general too small for adjustments of the
crude IRR.
Discussion
We hypothesized that antidepressants influence the fetal
lung development because of the involvement of 5-HT and
noradrenergic receptors in the development of the mamma-
lian respiratory rhythm generator and the production of
surfactant. We tested this hypothesis by counting the num-
ber of prescriptions of drugs for pulmonary diseases of
children who were exposed in utero to antidepressants as a
proxy for developmental respiratory tract changes. We
found a significant increase in the use of drugs for pulmo-
nary disease after in utero exposure to SSRIs any time
during pregnancy (IRR01.17, 95 % CI 1.16–1.18) after
adjustment for in utero exposure to antibiotics. Also, an
increased IRR of children exposed in utero to SSRIs during
at least the first trimester was found (IRR01.18, 95 % CI
1.17–1.20). The increase was seen in all periods of preg-
nancy; however, probably because of our small sample size,
statistical significance was only reached in the first trimester
or at any time during pregnancy. We also found an increase
in the use of drugs for pulmonary disease after in utero
exposure to TCAs (IRR01.07, 95 % CI 0.96–1.19), also
after adjustment of in utero exposure to antibiotics.
Our results are in line with other findings. Kozyrskyj et
al. reported that maternal distress, using prescriptions of
antidepressants and anxiolytics, leads in 8.3 % of children
exposed to antidepressants to asthmatic diseases [36]. The
question now arises, what is the contribution of antidepres-
sants compared with anxiolytics in the study of Kozyrskyj et
Table 1 Group characteristics and possible confounding factors
Reference group (%) Exposed to SSRIs (%) Exposed to TCA (%) p value
Total 35,033 (100 %) 436 (100 %) 67 (100 %)
Maternal use of antibiotics 7,027 (20.1 %) 115 (26.4 %) 17 (25.4 %) 0.005
Maternal use of benzodiazepines 883 (2.5 %) 121 (27.8 %) 19 (28.4 %) <0.001
Maternal age>30 years at delivery 15,585 (44.5 %) 244 (56.0 %) 34 (50.7 %) <0.001
Maternal use of insulin 269 (0.8 %) 2 (0.5 %) 1 (1.5 %) 0.896
Maternal use of drugs for pulmonary diseases 1,432 (4.1 %) 21 (4.8 %) 6 (9.0 %) 0.285
SSRIs 0 serotonin reuptake inhibitors, TCAs 0 tricyclic antidepressants
Table 2 The use of drugs for pulmonary diseases after in utero exposure to SSRIs or TCAs
Group Pregnancy period Children
exposed




IR (years) IRR (95 % CI) IRR (95 % CI)
aadjusteda
Reference Anytime 35,033 6,722 13,244.12 0.508 1 1
Exposed
to SSRIs
Anytime 436 83 136 0.61 1.20 (0.97– 1.49) 1.17 (1.16– 1.18)
Only 1st trimester 163 30 56.7 0.53 1.04 (0.73– 1.49) 1.03 (0.98– 1.09)
Only 2nd and 3rd trimester 26 3 4.72 0.64 1.26 (0.41– 3.91) b
At least 1st trimester 374 74 121.88 0.61 1.20 (0.96– 1.51) 1.18 (1.17–1.2)
At least 2nd and 3rd trimester 195 39 59.11 0.66 1.30 (0.95– 1.78) b
Exposed
to TCAs
Anytime 67 12 21.47 0.56 1.10 (0.63– 1.94) 1.07 (0.96– 1.19)
Only 1st trimester 31 8 13.47 0.59 1.16 (0.58– 2.32) b
Only 2nd and 3rd trimester 3 0
At least 1st trimester 57 11 20.93 0.53 1.04 (0.58– 1.88) b
At least 2nd and 3rd trimester 24 3 7.46 0.4 0.79 (0.25– 2.44) b
IR 0 incidence risk, IRR 0 incidence risk ratio
a Adjusted for maternal antibiotic use
b Insufficient number of cases for adjustment
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al., because he took antidepressants and anxiolytics together
in his analysis, whereas we found an increased risk of SSRIs
alone. Recently, Reis and Kallen reported an increase in
neonatal respiratory diagnoses after in utero exposure to
antidepressants [21]. Both studies suggest an increase in
the use of drugs for pulmonary disease due to in utero
exposure to antidepressants.
Drug-related factors that might be involved in the use of
drugs for pulmonary diseases in childhood are gestational
diabetes (use of insulin), intrauterine exposure to sympatho-
mimetics (maternal use of drugs for pulmonary diseases),
maternal antibiotic use during pregnancy, and maternal use
of benzodiazepines [37, 38]. These factors were used for a
co-variate analysis in our database. Another finding that
depression itself is related to the occurrence of asthma via
neuroimmunomodulatory pathways led to us investigating
the role of benzodiazepines, which could serve as a surro-
gate drug for depression and anxiety [36]. Further to over-
come confounding by indication, we excluded mothers who
use less than 0.5 DDD of TCA, which is probably used for
neuropathic pain. Because other factors were not different
between the exposed and the unexposed groups, we did not
correct for maternal use of insulin, and maternal use of drugs
for pulmonary disease.
Of importance is that maternal and/or paternal smoking
in the presence of their children could not be detected in our
database-oriented study. Therefore, further research is man-
datory. It is well known that the incidence of smoking
among psychiatric patients is higher than in a nonpsychiatric
population [39]. The negative effects on the respiratory
system of maternal smoking may lead to increased use of
drugs for pulmonary diseases in mother and child. Indepen-
dently, maternal pulmonary diseases affect fetal respiratory
tract development [37, 38]. It was also shown that maternal
asthma is statistically significantly associated with congen-
ital anomalies of the respiratory system, which might further
increase the use of drugs for pulmonary diseases [40]. We
found that maternal asthma expressed as the use of drugs for
pulmonary disease did not lead to an increase in the use of
drugs for pulmonary disease in the child, however slightly
statistically nonsignificant. Because there was no difference
between the exposed and the non-exposed group in the use
of maternal drugs for pulmonary disease, we did not adjust
for maternal use of drugs for pulmonary disease.
Remarkable is our finding that despite pharmacological
support for developmental changes of the respiratory tract
due to in utero exposure of antidepressants, we did not find
differences between the different periods of pregnancy and
the class of antidepressants and the increase in the use of
drugs for pulmonary diseases in children. Probably, the low
number of children exposed in only the second and third
trimesters is the reason for this.
The strength of our study is that we searched for and
found a pharmacological explanation for the possible in-
volvement of antidepressants in the developing fetus, and
that we could test this hypothesis with the use of prescrip-
tion data from mother and child. With this approach, using
prescriptions of drugs as a proxy for diseases or influence on
developmental processes, we could also correct for possible
confounding variables like in utero exposure to antibiotics.
However, there are also some limitations in using an admin-
istrative prescription database because we do not know
whether the drugs were actually taken. If the women had
not been compliant, our results would have been an under-
estimation of the real effect. Another limitation is that over-
the-counter drugs (OTC) are lacking. These drugs may act
as a confounder for our results. SSRIs and TCAs are pre-
scribed for treating depression, but also for treating anxiety
and personality disorders. These diseases or the behavioural
changes of the mothers may be associated with the use of
drugs for pulmonary diseases. We do not have information
about the indication for the prescribed drugs, and therefore
confounding by indication is still possible. Only randomized
controlled follow-up studies could prevent this form of
confounding.
Tricyclic antidepressants and serotonin reuptake inhibitors
also bind to receptors that were not investigated (muscarine-
M-3-receptor, histamine-H-1-receptor), but the function of
these receptors in the ontogeny of the respiratory tract is still
unclear.
Table 3 The use of drugs for pulmonary diseases after in utero exposure to possible confounders
Group Children
exposed




I (years) IRR IRR (95 % CI)
Reference 35,536 6,807 13,244.12 0.51 1 1
In utero exposure to antibiotics 7,159 1,672 3,030.12 0.55 1.08 1.08 (1.02–1.14)
in utero exposure to benzodiazepines 1,027 227 484.45 0.47 0.92 0.92 (0.81–1.05)
Children with a mother aged > 30 at delivery 15,863 2,877 5435.73 0.53 1.04 1.04 (1.00–1.09)
In utero exposure to insulin 272 49 67.15 0.73 1.43 1.43 (1.08–1.89)
In utero exposure to drugs for pulmonary disease 1,459 487 866.65 0.56 1.1 1.10 (1.00–1.21)
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